Siparex has acquired a majority stake in Sodikart
Evolem has sold Sodikart to Siparex Group.
Siparex Group is an independent French private equity specialist with US$3 billion capital under management. The group focuses on the development of companies and their transformation.
Founded in 1981, Sodikart is the world leading designer and manufacturer of karts for leisure and competition, the sale of accessories and spare parts, leisure center management and timing solutions, track design and event organization.
Evolem is a family office created in 1997 by Bruno Rousset, founder of April. It promotes entrepreneurs, employment, education and environment. Evolem supports SMEs to turn them into mid-cap companies, helps startups establish their model and supports non-profit projects to multiply their impact. Since its creation, Evolem has accompanied more than a hundred companies, which represents 6,000 jobs and nearly US$790 million total aggregate sales.
Oaklins’ team in France acted as the exclusive buy-side advisor to Siparex Group in this transaction.
Contáctese con el equipo de la transacción
Transacciones relacionadas
OBI Group has acquired the OBI and individual DIG stores from Migros
As part of a strategic review, Migros has decided to divest its DIY business, which included several “Do It + Garden” and “OBI” locations. Migros had operated the Swiss OBI stores as a franchisee. In OBI Group Holding, Migros has found the ideal partner to ensure continuity for both its customers and employees.
Ver másDen Berk Délice accelerates growth through strategic partnership
Den Berk Délice, a leading Belgian grower of specialty tomatoes, has entered a strategic partnership with Egeria, an independent investment firm, to realize its next growth phase.
Ver másXiel Limited has been acquired by MIS Healthcare
MIS Healthcare, a leading distributor in medical imaging, has successfully acquired Xiel Limited. This strategic acquisition merges MIS Healthcare’s extensive radiotherapy portfolio with Xiel’s specialized expertise in nuclear medicine, radiotherapy and diagnostic radiology. The merger strengthens both companies’ positions in the rapidly growing fields of oncology and nuclear medicine, promising to deliver exceptional value to the healthcare community in the UK and Ireland.
Ver más